Literature DB >> 8292069

In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis).

O Janssen1, A Scheffler, D Kabelitz.   

Abstract

The in vitro effects of therapeutically administered mistletoe extracts (ABNOBAviscum) and pure mistletoe lectins (mainly mistletoe lectin I) on a variety of human and murine tumor cell lines have been investigated. Mistletoe extracts and purified mistletoe lectins inhibited in vitro the growth of all tumor cell lines tested including B cell hybridomas, P815, EL-4, Ke37, MOLT-4 and U937. The mechanism of growth arrest was shown to be due to the induction of programmed cell death (apoptosis). Thus, fragmentation of genomic DNA into oligonucleosomal bands of approximately 200 base pairs in length was observed within 20 h when tumor cells were incubated with mistletoe extracts or lectins. These data point to a rational basis for the direct cytotoxic effects of mistletoe extracts and lectins apart from the postulated immunostimulatory properties of these agents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8292069

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  16 in total

1.  Modulation of CD4+ T-cell activation by CD95 co-stimulation.

Authors:  M Paulsen; S Valentin; B Mathew; S Adam-Klages; U Bertsch; I Lavrik; P H Krammer; D Kabelitz; O Janssen
Journal:  Cell Death Differ       Date:  2010-11-05       Impact factor: 15.828

2.  Effect of a mistletoe extract (Iscador QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices.

Authors:  G Nikolai; P Friedl; M Werner; B Niggemann; K S Zänker
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-10       Impact factor: 2.416

3.  Astragalus membranaceus lectin (AML) induces caspase-dependent apoptosis in human leukemia cells.

Authors:  L H Huang; Q J Yan; N K Kopparapu; Z Q Jiang; Y Sun
Journal:  Cell Prolif       Date:  2011-12-16       Impact factor: 6.831

4.  Carbohydrate binding and resistance to proteolysis control insecticidal activity of Griffonia simplicifolia lectin II.

Authors:  K Zhu-Salzman; R E Shade; H Koiwa; R A Salzman; M Narasimhan; R A Bressan; P M Hasegawa; L L Murdock
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

5.  Oncopharmacological Perspectives of a Plant Lectin (Viscum album Agglutinin-I): Overview of Recent Results from In vitro Experiments and In vivo Animal Models, and Their Possible Relevance for Clinical Applications.

Authors:  Tibor Hajtó; Katarina Hostanska; Timea Berki; László Pálinkás; Ferenc Boldizsár; Péter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2005-01-28       Impact factor: 2.629

6.  Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro.

Authors:  Ulrike Weissenstein; Matthias Kunz; Konrad Urech; Stephan Baumgartner
Journal:  BMC Complement Altern Med       Date:  2014-01-08       Impact factor: 3.659

7.  Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo.

Authors:  Christian M Strüh; Sebastian Jäger; Astrid Kersten; Christoph M Schempp; Armin Scheffler; Stefan F Martin
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

8.  Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.

Authors:  M Mabed; L El-Helw; S Shamaa
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

9.  Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation.

Authors:  K Hostanska; V Vuong; S Rocha; M S Soengas; C Glanzmann; R Saller; S Bodis; M Pruschy
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

10.  A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients.

Authors:  Alessandra Longhi; Marcus Reif; Erminia Mariani; Stefano Ferrari
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-31       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.